AdventHealth names David Banks as CEO and president
Banks replaces Terry Shaw, who announced he was retiring in December.
AdventHealth names David Banks as CEO and president Read More »
Banks replaces Terry Shaw, who announced he was retiring in December.
AdventHealth names David Banks as CEO and president Read More »
The FTC chair had previously been recused from the lawsuit. But after consulting with ethics lawyers, Ferguson changed his mind so the case could move forward, he said on Thursday.
FTC lawsuit against PBMs can move forward after Ferguson rejoins case Read More »
While it’s not unusual for certain positions to turn over with a new administration, the number of senior-level FDA staffers who have recently left the agency is unprecedented. The lack of communication, transparency and human decency is as well.
FDA Gutted Under Trump, RFK Jr., With More Than Half of Senior Leadership Now Gone Read More »
Eleven percent of people surveyed — roughly 29 million people — said they were unable to afford medication and care within the past three months.
More Americans say they can’t afford healthcare: Gallup Read More »
The FDA has asked for another well-controlled trial to establish the efficacy of reproxalap in dry eye disease.
Aldeyra Shares Crash as Dry Eye Drug Gets Second Rejection from FDA Read More »
In the Phase III MITIGATE trial, Uplizna cut IgG4-related disease flares by 84% versus placebo.
Amgen Wins Expansion for Uplizna as First Drug for IgG4-Related Disease Read More »
The FDA derives just under half of its yearly funding from pharma user fees, which help support its operations and fund employee salaries. An analysis from Agency IQ suggests that the agency is dangerously close to losing it all.
FDA Faces ‘Catastrophic Collapse’ as Massive Layoffs Endanger User Fee Program Read More »
Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that has shown the ability in preclinical studies to cross the blood-brain barrier.
Lilly Throws Sangamo a Lifeline With Pact Worth Potential $1.4B+ Read More »
La leucemia linfoblástica aguda de células B (LLA-B) es un tipo de cáncer de la sangre muy agresivo y potencialmente mortal. Es el cáncer infantil más común, en concreto representa el 35 % de los casos pediátricos, pero puede afectar a personas de cua …
Tratamiento más eficaz contra la leucemia linfoblástica aguda de células B Read More »
La manera en que eliges tu próximo destino de vacaciones ya no depende solo de las recomendaciones de un amigo o de un reportaje en televisión. Hoy, los datos influyen mucho más de lo que imaginas. Cada búsqueda que haces, cada clic en una oferta de vuelos o cad …
Big Data y turismo: cómo los datos están cambiando la forma en que elegimos destinos Read More »